Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice

25/03/2024
01/08/2025
EU PAS number:
EUPAS1000000083
Study
Finalised
Data sources

Data source(s)

Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes
Data characterisation

Data characterisation conducted

Yes